| Dr Cort Berne Leavitt, MD | |
|
1380 E Medical Center Dr, St George, UT 84790-2123 | |
| (435) 251-2992 | |
| Not Available |
| Full Name | Dr Cort Berne Leavitt |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 13 Years |
| Location | 1380 E Medical Center Dr, St George, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326394693 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 15225 (Nevada) | Secondary |
| 207Q00000X | Family Medicine | 9674228-1205 (Utah) | Secondary |
| 208M00000X | Hospitalist | 9674228-1205 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Intermountain Homecare Hospice, St George | St george, UT | Hospice |
| Dixie Regional Medical Center | St george, UT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Writing in the American Public Health Association International Health Section's "IH-Blog," Jessica Keralis, IH Communications Committee chair, highlights three recently released advocacy videos by Médecins Sans Frontières discussing child vaccines and a subsequent conversation between MSF and the GAVI Alliance over vaccine pricing.
Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Writing in the American Public Health Association International Health Section's "IH-Blog," Jessica Keralis, IH Communications Committee chair, highlights three recently released advocacy videos by Médecins Sans Frontières discussing child vaccines and a subsequent conversation between MSF and the GAVI Alliance over vaccine pricing.
Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Cort Berne Leavitt, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (435) 251-2992 | Dr Cort Berne Leavitt, MD 1380 E Medical Center Dr, St George, UT 84790-2123 Ph: (435) 251-2992 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today announced the selection of its first RNAi therapeutic product candidate to advance into development.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
Writing in the American Public Health Association International Health Section's "IH-Blog," Jessica Keralis, IH Communications Committee chair, highlights three recently released advocacy videos by Médecins Sans Frontières discussing child vaccines and a subsequent conversation between MSF and the GAVI Alliance over vaccine pricing.
Tengion, Inc., a regenerative medicine company focused on discovering, developing, manufacturing and commercializing neo-organs and neo-tissues, today announced the completion of its initial public offering of 6,000,000 shares of common stock at a price of $5.00 per share. The net proceeds of the offering to Tengion, after deducting underwriting discounts and commissions and estimated offering expenses payable by Tengion, were approximately $26.0 million.
› Verified 4 days ago
Tyler Robertson, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 Fax: 435-688-6222 | |
William Wesley Barney, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2900 Fax: 435-251-2901 | |
Dr. Jason Lindsay Hansen, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 | |
Matthew Stilson Williams, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 | |
Sarah Wei Wu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 577 S River Rd, St George, UT 84790 Phone: 435-688-6200 | |
Dr. Kerri N Smith, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1380 E Medical Center Dr, Suite 3100, St George, UT 84790 Phone: 435-251-2740 |